found that ibrutinib in combination with PD-1/PD-L1 blockade in Eμ-TCL1 mice reduced tumor burden and increased percentage of cytotoxic CD8+T cells over ibrutinib single agent treatment (48). Here, CD8A is linked to neoplasm.